GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2 Jemperli combo data in lung cancer

BARCELONA — GSK and iTeos have unveiled positive mid-phase data for their PD-1 plus TIGIT doublet in certain lung cancer patients, bolstering expectations for an ongoing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

The Endpoints 100: The biotech industry braces for Trump 2.0

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 12, 2024

Cory Firth is Committed to a Career Empowering Wellbeing – Podcast Episode #44 | Psychedelic Invest

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Cory Firth, the Co-Founder of Neuma. On his LinkedIn profile, Cory

January 24, 2024

Bispecifics-Based Combination Therapy in Multiple Myeloma

At the American Society of Clinical Oncology (ASCO) annual meeting, promising results were reported from two trials that evaluated a combination of two bispecific antibodies

July 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.